Department of Ophthalmology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
Hsin Ho Mei Eye Clinic, Songshan Branch, Taipei, Taiwan.
Eur J Ophthalmol. 2021 May;31(3):1267-1280. doi: 10.1177/1120672120913012. Epub 2020 Mar 31.
Using optical coherence tomography angiography to assess and compare changes in pathological vascular tissue, including choroidal neovascularization in neovascular age-related macular degeneration and polypoidal complex in polypoidal choroidal vasculopathy, after treatment with anti-vascular endothelial growth factor.
This is a retrospective observational case series study. Clinical data were collected, including that on the best-corrected visual acuity and images of spectrum domain optical coherence tomography and optical coherence tomography angiography of consecutive patients with macula-involved lesions, active pathological vascular tissue in neovascular age-related macular degeneration, and polypoidal complex in polypoidal choroidal vasculopathy who were treated with anti-vascular endothelial growth factor injection. The primary outcome measures were the lesion area, flow density, and flow area of the pathological vascular tissue obtained in optical coherence tomography angiography before treatment, as well as week-1 (W1) and week-5 (W5) after treatment. The secondary outcome measures were the best-corrected visual acuity and the anatomic changes in spectrum domain optical coherence tomography at the same periods.
A total of 86 eyes in 79 patients (mean age: 73.10 ± 10.10 (range = 50-91) years, 45 males (57%), of which two eyes were treatment-naïve) underwent one section of intravitreal treatment. Of which 44 eyes (40 patients) were diagnosed as typical neovascular age-related macular degeneration and 42 eyes (39 patients) as polypoidal choroidal vasculopathy. The sensitivity for detecting choroidal neovascularization in neovascular age-related macular degeneration and polypoidal complex in polypoidal choroidal vasculopathy was 75.00% (33/44) and 69.05% (29/42), respectively. There was no significant difference in the detection rate between neovascular age-related macular degeneration and polypoidal choroidal vasculopathy ( = 0.54). In the detectable group, there were significant decrease in lesion area and flow area in the optical coherence tomography angiography images after anti-vascular endothelial growth factor treatment in both the neovascular age-related macular degeneration group (lesion area: W1 = -26.94 ± 19.50%, W5 = -35.52 ± 30.85%, all s < 0.001; flow area: W1 = -26.22 ± 25.23%, W5 = -32.24 ± 32.07%, all s < 0.001) and the polypoidal choroidal vasculopathy group (lesion area: W1 = -25.19 ± 20.27%, W5 = -31.55 ± 27.04%, all s < 0.001; flow area: W1 = -21.83 ± 26.29%, W5 = -28.31 ± 30.72%, all s < 0.001). The central subfield retinal thickness in spectrum domain optical coherence tomography also showed similar amelioration in both groups. However, the flow density in optical coherence tomography angiography image and the visual outcome did not reveal any significant difference before or after intravitreal injections, and neither were there significant differences between the neovascular age-related macular degeneration and polypoidal choroidal vasculopathy groups. Concerning the effect on the optical coherence tomography angiography images of pathological vascular tissue, there were no statistical differences among different anti-vascular endothelial growth factor agents (i.e. aflibercept, ranibizumab, and bevacizumab).
Our study revealed that optical coherence tomography angiography can be used noninvasively and quantitatively to assess the detailed pathologic vascular structures in both neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Our study also demonstrated that anti-vascular endothelial growth factor could effectively decrease the lesion size and flow area of both the choroidal neovascularization in neovascular age-related macular degeneration cases and the polypoidal complex in polypoidal choroidal vasculopathy cases; the effects were similar in both diseases.
利用光相干断层扫描血管造影术评估和比较新生血管性年龄相关性黄斑变性中的脉络膜新生血管和息肉状脉络膜血管病变中的息肉状复合体的病理性血管组织的变化,这些变化是在接受抗血管内皮生长因子治疗后出现的。
这是一项回顾性观察性病例系列研究。收集了连续的黄斑受累病变、新生血管性年龄相关性黄斑变性中活跃的病理性血管组织和息肉状脉络膜血管病变中息肉状复合体的患者的最佳矫正视力和光谱域光相干断层扫描及光相干断层扫描血管造影图像的临床数据。这些患者均接受了抗血管内皮生长因子注射治疗。主要观察指标是治疗前光相干断层扫描血管造影中病理性血管组织的病变面积、血流密度和血流面积,以及治疗后第 1 周(W1)和第 5 周(W5)的这些指标。次要观察指标是同期的最佳矫正视力和光谱域光相干断层扫描的解剖学变化。
共有 79 例患者的 86 只眼(平均年龄:73.10±10.10 岁[范围:50-91 岁],男性 45 例[57%],其中 2 只眼为初次治疗)接受了 1 次眼内治疗。其中 44 只眼(40 例患者)被诊断为典型的新生血管性年龄相关性黄斑变性,42 只眼(39 例患者)为息肉状脉络膜血管病变。在检测新生血管性年龄相关性黄斑变性中的脉络膜新生血管和息肉状脉络膜血管病变中的息肉状复合体时,光相干断层扫描血管造影的敏感性分别为 75.00%(33/44)和 69.05%(29/42)。新生血管性年龄相关性黄斑变性和息肉状脉络膜血管病变的检测率之间没有显著差异(P=0.54)。在可检测的组中,抗血管内皮生长因子治疗后,新生血管性年龄相关性黄斑变性组(病变面积:W1=-26.94±19.50%,W5=-35.52±30.85%,均 P<0.001;血流面积:W1=-26.22±25.23%,W5=-32.24±32.07%,均 P<0.001)和息肉状脉络膜血管病变组(病变面积:W1=-25.19±20.27%,W5=-31.55±27.04%,均 P<0.001;血流面积:W1=-21.83±26.29%,W5=-28.31±30.72%,均 P<0.001)的光相干断层扫描血管造影图像中的病变面积和血流面积均显著减小。光谱域光相干断层扫描的中心视网膜厚度也在两组中均显示出类似的改善。然而,光相干断层扫描血管造影图像中的血流密度和视力结果在眼内注射前后均未显示出任何显著差异,新生血管性年龄相关性黄斑变性和息肉状脉络膜血管病变组之间也没有显著差异。关于不同抗血管内皮生长因子药物(即阿柏西普、雷珠单抗和贝伐单抗)对病理性血管组织的光相干断层扫描血管造影图像的影响,没有统计学差异。
我们的研究表明,光相干断层扫描血管造影术可以无创、定量地评估新生血管性年龄相关性黄斑变性和息肉状脉络膜血管病变中的详细病理血管结构。我们的研究还表明,抗血管内皮生长因子可以有效减少新生血管性年龄相关性黄斑变性病例中的脉络膜新生血管和息肉状脉络膜血管病变病例中的息肉状复合体的病变大小和血流面积;两种疾病的效果相似。